



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of  
**PARKER et al.**

Examiner: **HELMS, Larry Ronald**

Art Unit: **1642**

Application No.: **09/719,758**

Filed: **January 4, 2002**

Title: **MONOCLONAL ANTIBODIES  
DIRECTED AGAINST THE G3BP  
PROTEIN AND USES**

<b>Certificate of Mailing or Transmission</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.	
Date of Deposit	<u>Aug 2, 2005</u>
Printed Name of Person Signing Certificate	<u>Delia Coughlin</u>
Signature	<u>Delia Coughlin</u>

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Mail Stop Sequence  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

Karen Krupen  
Karen I. Krupen, Reg. No. 34,647  
Attorney/Agent for Applicant

sanofi-aventis  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-  
Telefax (908) 231-2626

Aventis Docket No. ST98017 US PCT